Revolution Medicines shared on LinkedIn:
“We are honored to receive the California Life Sciences (CLS) Pantheon Award for Biopharma Product of the Year.
Adrian Gill, Executive Vice President and Head of Early Discovery, accepted the award on behalf of Revolution Medicines last week.
The recognition reflects the persistence, curiosity and collaboration of colleagues across our organization and the broader California biotech community who have challenged long-held assumptions about targeting RAS-driven cancers.
Most importantly, we are grateful to the patients, families, clinical trial investigators and care teams whose partnership makes this work possible.”
Read more: Meet the Winners and Finalists of the 23rd Annual Pantheon Awards.”
“We are proud to be part of a California biotech community that shares our dedication to patients and our passion for tackling scientific challenges. We’re honored to receive this recognition alongside such remarkable companies and leaders.” – Adrian Gill․
You can also read: The European Commission Approves Revolution Medicines’ Daraxonrasib for Metastatic Pancreatic Cancer.
